Nkarta (NKTX) Competitors $1.97 0.00 (0.00%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$1.96 0.00 (-0.25%) As of 09/15/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NKTX vs. MRVI, ORGO, KROS, TERN, MGTX, PVLA, ANAB, ORKA, XNCR, and SIGAShould you be buying Nkarta stock or one of its competitors? The main competitors of Nkarta include Maravai LifeSciences (MRVI), Organogenesis (ORGO), Keros Therapeutics (KROS), Terns Pharmaceuticals (TERN), MeiraGTx (MGTX), Palvella Therapeutics (PVLA), AnaptysBio (ANAB), Oruka Therapeutics (ORKA), Xencor (XNCR), and Siga Technologies (SIGA). These companies are all part of the "pharmaceutical products" industry. Nkarta vs. Its Competitors Maravai LifeSciences Organogenesis Keros Therapeutics Terns Pharmaceuticals MeiraGTx Palvella Therapeutics AnaptysBio Oruka Therapeutics Xencor Siga Technologies Nkarta (NASDAQ:NKTX) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk. Which has better valuation and earnings, NKTX or MRVI? Nkarta has higher earnings, but lower revenue than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNkartaN/AN/A-$108.79M-$1.48-1.33Maravai LifeSciences$259.18M2.68-$144.85M-$1.36-2.00 Is NKTX or MRVI more profitable? Nkarta has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -90.03%. Maravai LifeSciences' return on equity of -17.60% beat Nkarta's return on equity.Company Net Margins Return on Equity Return on Assets NkartaN/A -27.74% -22.38% Maravai LifeSciences -90.03%-17.60%-9.30% Do insiders & institutionals believe in NKTX or MRVI? 80.5% of Nkarta shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 8.4% of Nkarta shares are owned by insiders. Comparatively, 2.1% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts rate NKTX or MRVI? Nkarta currently has a consensus target price of $13.60, indicating a potential upside of 590.36%. Maravai LifeSciences has a consensus target price of $5.22, indicating a potential upside of 91.87%. Given Nkarta's stronger consensus rating and higher possible upside, analysts clearly believe Nkarta is more favorable than Maravai LifeSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nkarta 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Maravai LifeSciences 1 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.18 Does the media prefer NKTX or MRVI? In the previous week, Maravai LifeSciences had 4 more articles in the media than Nkarta. MarketBeat recorded 5 mentions for Maravai LifeSciences and 1 mentions for Nkarta. Nkarta's average media sentiment score of 1.75 beat Maravai LifeSciences' score of 1.36 indicating that Nkarta is being referred to more favorably in the media. Company Overall Sentiment Nkarta Very Positive Maravai LifeSciences Positive Which has more risk and volatility, NKTX or MRVI? Nkarta has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. SummaryNkarta beats Maravai LifeSciences on 11 of the 16 factors compared between the two stocks. Get Nkarta News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKTX vs. The Competition Export to ExcelMetricNkartaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$139.92M$3.15B$5.79B$10.18BDividend YieldN/A2.33%5.73%4.61%P/E Ratio-1.3321.2474.8626.39Price / SalesN/A466.65543.67125.97Price / CashN/A44.4425.8129.91Price / Book0.349.6413.256.28Net Income-$108.79M-$53.20M$3.29B$270.38M7 Day Performance-4.83%0.07%0.07%1.89%1 Month Performance-15.45%4.27%4.60%6.01%1 Year Performance-65.13%9.62%72.95%25.26% Nkarta Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKTXNkarta2.3323 of 5 stars$1.97flat$13.60+590.4%-65.5%$139.92MN/A-1.33140Positive NewsMRVIMaravai LifeSciences3.5377 of 5 stars$2.44-2.8%$5.22+113.9%-67.6%$640.96M$259.18M-1.79610Positive NewsORGOOrganogenesis3.9948 of 5 stars$4.77-4.6%$7.50+57.2%+76.5%$634.29M$482.04M-34.07950Positive NewsHigh Trading VolumeKROSKeros Therapeutics3.3331 of 5 stars$15.47-0.8%$30.00+93.9%-72.7%$633.19M$3.55M49.90100Positive NewsTERNTerns Pharmaceuticals3.9944 of 5 stars$7.28+0.8%$15.61+114.4%-20.4%$631.83MN/A-7.0040Positive NewsMGTXMeiraGTx4.1988 of 5 stars$7.47-2.9%$24.00+221.3%+72.5%$618.64M$33.28M-3.66300News CoveragePositive NewsPVLAPalvella Therapeutics2.1553 of 5 stars$55.02-1.2%$58.50+6.3%N/A$615.80M$42.81M-4.55N/ANews CoverageANABAnaptysBio2.3221 of 5 stars$22.19+1.3%$46.13+107.9%-50.0%$613.13M$91.28M-4.95100Positive NewsORKAOruka Therapeutics2.2308 of 5 stars$15.80-3.4%$40.38+155.5%-38.7%$612.32MN/A-5.62N/AXNCRXencor3.9415 of 5 stars$8.41-1.6%$22.25+164.6%-60.5%$609.81M$110.49M-3.50280Positive NewsSIGASiga Technologies1.4377 of 5 stars$8.66+2.9%N/A+13.9%$602.92M$138.72M7.6640 Related Companies and Tools Related Companies Maravai LifeSciences Competitors Organogenesis Competitors Keros Therapeutics Competitors Terns Pharmaceuticals Competitors MeiraGTx Competitors Palvella Therapeutics Competitors AnaptysBio Competitors Oruka Therapeutics Competitors Xencor Competitors Siga Technologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NKTX) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf you own dollars, read this...Former Goldman Exec: "A Strange Day Is Coming to America" Dr. David Eifrig, who warned of inflation months ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nkarta, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nkarta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NKTX Stock Alerts